Website
N/ATelephone
61.13.0097.4621
Address
324 Queen Street Brisbane, Queensland (QLD) 4000
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.14 - 0.3
Trade Value (12mth)
AU$14,297.00
1 week
-5.71%
1 month
-2.94%
YTD
-8.33%
1 year
-45.36%
All time high
0.42
EPS 3 yr Growth
87.60%
EBITDA Margin
-197.90%
Operating Cashflow
-$16m
Free Cash Flow Return
-38.70%
ROIC
-49.60%
Interest Coverage
-345.60
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
448m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.53
Date | Announcements |
---|---|
10 October 24 |
Strategic transfer of Microba Research Services Unit to CMC
×
Strategic transfer of Microba Research Services Unit to CMC |
02 October 24 |
Date of AGM and Closing Date for Director Nominations
×
Date of AGM and Closing Date for Director Nominations |
25 September 24 |
Microba Presents at ASX Small & Mid Cap Conference
×
Microba Presents at ASX Small & Mid Cap Conference |
02 September 24 |
Change of Joint Company Secretary Role
×
Change of Joint Company Secretary Role |
29 August 24 |
2024 Corporate Governance Statement
×
2024 Corporate Governance Statement |
29 August 24 |
2024 Appendix 4G
×
2024 Appendix 4G |
29 August 24 |
2024 Annual Report & Appendix 4E
×
2024 Annual Report & Appendix 4E |
25 July 24 |
Q4 FY24 Quarterly Activities Report & Appendix 4C
×
Q4 FY24 Quarterly Activities Report & Appendix 4C |
25 July 24 |
Q4 FY24 Quarterly Investor Presentation & Webinar
×
Q4 FY24 Quarterly Investor Presentation & Webinar |
23 July 24 |
Details of Q4 FY24 Quarterly Report, Appendix 4C & Webinar
×
Details of Q4 FY24 Quarterly Report, Appendix 4C & Webinar |
12 July 24 |
Microba Diagnostics Business Update to Bioshares Summit
×
Microba Diagnostics Business Update to Bioshares Summit |
10 July 24 |
Notification of cessation of securities - MAP
×
Notification of cessation of securities - MAP |
28 June 24 |
Completion of Autoimmune Program with Ginkgo Bioworks
×
Completion of Autoimmune Program with Ginkgo Bioworks |
25 June 24 |
Release of Securities from Voluntary Escrow
×
Release of Securities from Voluntary Escrow |
03 June 24 |
Notification of cessation of securities - MAP
×
Notification of cessation of securities - MAP |
23 April 24 |
Q3 FY24 Quarterly Activities Report & Appendix 4C
×
Q3 FY24 Quarterly Activities Report & Appendix 4C |
23 April 24 |
Q3 FY24 Quarterly Investor Presentation
×
Q3 FY24 Quarterly Investor Presentation |
18 April 24 |
Details of Q3 FY24 Quarterly Report, Appendix 4C & Webinar
×
Details of Q3 FY24 Quarterly Report, Appendix 4C & Webinar |
16 April 24 |
Microba Launches Investor Hub for Investor Engagement
×
Microba Launches Investor Hub for Investor Engagement |
10 April 24 |
Notification of cessation of securities - MAP
×
Notification of cessation of securities - MAP |
10 April 24 |
Microba receives $6.08 million R&D Tax Incentive Refund
×
Microba receives $6.08 million R&D Tax Incentive Refund |
05 April 24 |
Application for quotation of securities - MAP
×
Application for quotation of securities - MAP |
05 April 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
25 March 24 |
Release of Restricted Securities
×
Release of Restricted Securities |
13 March 24 |
MetaPanel Diagnostic Test Launched with Sonic Healthcare
×
MetaPanel Diagnostic Test Launched with Sonic Healthcare |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.